Latest From Optovue Inc.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced October-November 2015.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a monthly review of emerging In Vitro Diagnostic, Medical Device, and Pharmaceutical companies that have received venture funding. This month’s column covers deals announced October through November 2015.
OcuSciences Inc.'s OcuMet Beacon is a noninvasive and rapid diagnostic screening tool for retinal disease. The current ophthalmic standard of care, optical coherence tomography, evaluates structural change in retinal thickness or swelling after retinal damage has occurred, but OcuMet can provide a level of functional testing before damage occurs, which is especially important for latent diabetics or patients undiagnosed for retinal diseases.
After receiving a grant last year, CDRH researchers are working toward a consensus phantom eye model to allow for standardized bench testing for optical coherence tomography device submissions.
- Diagnostic Imaging Equipment & Supplies
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Optovue Inc.
- Senior Management
Jay Wei, CEO
Gordon Wong, VP, Fin.
Paul Kealey, SVP, Product Dev. & Bus. Strategy
Bill Shields, VP, International Sales
Tony Ko, PhD, VP, R&D
- Contact Info
Phone: (510) 623-8868
2800 Bayview Dr.
Fremont, CA 94538
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.